Back to top

marijuana: Archive

Sundeep Ganoria

Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?

GTBIF slides 30% YTD as rising costs, flat revenues and tight U.S. rules weigh on margins and investor sentiment.

ACBNegative Net Change GTBIFNegative Net Change CRLBFNegative Net Change CURLFNegative Net Change

Sundeep Ganoria

Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?

CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.

CGCNegative Net Change TLRYPositive Net Change ACBNegative Net Change CRLBFNegative Net Change

Sundeep Ganoria

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

JAZZNegative Net Change AXSMNegative Net Change HRMYNegative Net Change

Sundeep Ganoria

Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?

CURLF dives 46% YTD as domestic headwinds outweigh global growth; is it time to cash out or wait for a rebound?

CGCNegative Net Change TLRYPositive Net Change ACBNegative Net Change CURLFNegative Net Change

Sundeep Ganoria

Could the New Federal Bill Derail the U.S. Hemp Industry?

A proposed federal bill could upend the U.S. hemp market, threatening CBD and Delta-8 products now sold nationwide.

CGCNegative Net Change TLRYPositive Net Change CURLFNegative Net Change

Sundeep Ganoria

Cannabis Stock CGC Rallies 39% in Three Months: Time to Buy or Sell?

Canopy Growth surges 39% in three months as restructuring, margin gains and debt cuts renew investor interest.

CGCNegative Net Change TLRYPositive Net Change ACBNegative Net Change VFFNegative Net Change

Sundeep Ganoria

Cannabis Operator VFF Sells Fresh Produce Unit: How to Play the Stock?

After dropping its produce business, Village Farms sharpens its cannabis focus - boosting exports, margins and market share.

CGCNegative Net Change TLRYPositive Net Change ACBNegative Net Change VFFNegative Net Change

Sundeep Ganoria

Aurora Cannabis Stock Rises 30% YTD: Time to Buy or Sell?

ACB's 30% YTD rally reflects Q3 strength, but flat EPS estimates and consumer weakness keep analysts cautious about long-term upside.

CGCNegative Net Change TLRYPositive Net Change ACBNegative Net Change

Sundeep Ganoria

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.

NVONegative Net Change LLYPositive Net Change CRBPPositive Net Change SKYEPositive Net Change

Sundeep Ganoria

Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?

While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.

SNYNegative Net Change NVONegative Net Change CRBPPositive Net Change

Sundeep Ganoria

Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?

TLRY's pivot into beverages shows promise, but with falling cannabis sales and delisting risks, we recommend staying on the sidelines for now.

PMNegative Net Change JAZZNegative Net Change CRBPPositive Net Change TLRYPositive Net Change

Zacks Equity Research

JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook

Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.

JAZZNegative Net Change PBYIPositive Net Change NTLAPositive Net Change ELEVNegative Net Change

Zacks Equity Research

IIPR's Q1 Earnings Coming Up: Key Factors to Impact the Stock

IIPR's Q1 2025 results may be impacted by property repossessions/sales, rent deferrals and partial tenant payments.

IIPRPositive Net Change LAMRNegative Net Change EPRNegative Net Change

Sundeep Ganoria

Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings

Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.

JAZZNegative Net Change AMRXNegative Net Change

Sundeep Ganoria

3 Unconventional Cannabis Stocks to Watch in 2025

Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.

PMNegative Net Change JAZZNegative Net Change CRBPPositive Net Change

Sundeep Ganoria

Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?

Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.

JAZZNegative Net Change KNSAPositive Net Change CRDLNo Net Change

Sundeep Ganoria

JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?

Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.

JAZZNegative Net Change HRMYNegative Net Change

Sundeep Ganoria

Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?

Not your typical cannabis play. Discover why Jazz Pharma's FDA-approved CBD drug could make it a top cannabis stock to watch in 2025.

JAZZNegative Net Change TLRYPositive Net Change

Sweta Killa

Best & Worst ETF Zones of Q1

We have highlighted three ETFs, each from the best and worst-performing zones in the first quarter of 2025.

EPOLPositive Net Change SGDMPositive Net Change WGMINegative Net Change WEEDPositive Net Change EETHPositive Net Change BABOPositive Net Change

Urmimala Biswas

Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?

ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.

CGCNegative Net Change ACBNegative Net Change OGINegative Net Change

Zacks Equity Research

IIPR's Q4 Earnings Coming Up: Key Factors to Impact the Stock

Innovative Industrial's Q4 performance is likely to have been affected by a decline in contractual rent and property management fees and elevated expenses.

RHPNegative Net Change IIPRPositive Net Change PKNegative Net Change

Moumita C. Chattopadhyay

Is IIPR Stock a Buy, Hold or Sell After Its 49% Plunge in 3 Months?

With a volatile cannabis market and tenant risks, is IIPR's high yield sustainable, or will challenges overshadow its growth?

PLDPositive Net Change TRNOPositive Net Change IIPRPositive Net Change

Sweta Killa

Top & Flop ETFs of 2024

We have highlighted three ETFs each from the best and worst-performing zones in 2024.

TSLAPositive Net Change ARGTPositive Net Change GBTCNegative Net Change MAGSPositive Net Change BDRYNegative Net Change WEEDPositive Net Change ILITPositive Net Change

Mark Vickery

Markets Up Ahead of CPI, Jobless Claims Thursday

The Inflation Rate, which is CPI year over year headline, is expected to come down 20 basis points from +2.5% to +2.3%.

DALNegative Net Change AAPositive Net Change DPZNegative Net Change TLRYPositive Net Change

Sweta Killa

Best and Worst ETF Zones of Q2

Technology remained the best-performing sector of the second quarter on the AI drive while energy lagged.

SLVPNegative Net Change UNGPositive Net Change BDRYNegative Net Change PSILPositive Net Change WGMINegative Net Change WEEDPositive Net Change